Compass Therapeutics Reports $25.2 Million Net Loss in Q2 2026, Increases R&D Spending

Compass Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $25.2 million, compared to a net loss of $19.9 million for the same period in 2025. For the first half of 2026, the company recorded a net loss of $43.5 million, up from $36.5 million in the prior year. The increase in losses is attributed to higher operating expenses, which rose to $27.0 million for the quarter, a 28% increase from $21.1 million in the previous year. Research and development expenses accounted for $19.6 million, reflecting a 19% increase driven primarily by non-personnel project costs related to the development of its lead product candidate, tovecimig.

In terms of financial position, Compass Therapeutics reported total assets of $190.2 million as of June 30, 2026, a decrease from $219.6 million at the end of 2025. The decline in total assets was primarily due to a reduction in marketable securities, which fell from $178.3 million to $144.4 million. The company's cash and cash equivalents increased to $35.5 million from $30.6 million, indicating a positive cash flow from investing activities, which provided $33.5 million during the first half of 2026, largely from the sale of marketable securities.

Strategically, Compass Therapeutics is advancing its clinical pipeline, which includes four product candidates. The company recently announced positive results from its Phase 2/3 study of tovecimig in patients with biliary tract cancer, meeting its primary endpoint of overall response rate. The company expects to receive feedback from the FDA regarding this data in the third quarter of 2026, potentially paving the way for a Biologics License Application (BLA) filing later this year. Additionally, the company has initiated several investigator-sponsored trials for tovecimig in various cancer indications, further expanding its clinical research efforts.

Operationally, Compass Therapeutics has seen an increase in its employee headcount, which is expected to continue as the company ramps up its clinical development activities. The total number of shares outstanding increased to 180.1 million as of June 30, 2026, reflecting the exercise of stock options and stock-based compensation. The company anticipates that its existing cash resources will fund operations into 2028, although it acknowledges the need for additional funding to support ongoing clinical trials and potential commercialization efforts.

Looking ahead, Compass Therapeutics remains focused on advancing its product candidates through clinical development while managing its financial resources carefully. The company plans to finance its operations through a combination of equity and debt financing, collaborations, and strategic partnerships. However, it cautions that the timing and amount of future expenses will depend on various factors, including the progress of clinical trials and regulatory approvals, which may impact its ability to achieve profitability in the near term.